From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Enpp-1-IN-21 (compound 4g) is an inhibitor of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), with IC50 values for ENPP1 and ENPP3 at 0.45 and 0.19 μM, respectively .
Enpp-1-IN-14 (Compound 015) is a potent Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) inhibitor with an IC50 value of 32.38 nM for recombinant human ENPP-1. Enpp-1-IN-14 has anti-tumor activity .
Enpp-1-IN-20 (Compound 31) is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor, with an IC50 of 0.09 nM. Enpp-1-IN-20 has strongest inhibitory activity in the cell-based assay, with an IC50 of 8.8 nM. Enpp-1-IN-20 has significant potency in both ENPP1 inhibition and STING pathway stimulation in vitro. Enpp-1-IN-20 can be used for the research of cancer .
Enpp-1-IN-12 (compound 43) is a potent and orally active ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor, with a Ki of 41 nM. Enpp-1-IN-12 exhibits anti-tumor activity .
Enpp-1-IN-13 (Compound 1a) is an ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) inhibitor with IC50 values of 1.29 μM and 20.2 μM against ENPP1 and ENPP3, respectively. Enpp-1-IN-13 shows anticancer activity .
Enpp-1-IN-4 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1).Enpp-1-IN-4 has the potential for the research of cancer diseases (extracted from patent WO2019177971A1, compound 1) .
Enpp-1-IN-11 (compound 23) is a potent Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor with an Ki value of 45 nM. Enpp-1-IN-11 exhibits low clearance in human and mouse liver microsomes, good plasma stability in human and mouse plasma. Enpp-1-IN-11 can be used for researching anticancer .
Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and low oral bioavailability. Enpp-1-IN-25 can effectively activate the intracellular STING pathway by inhibiting cGAMP degradation. Enpp-1-IN-25 can enhance immune cell infiltration in the tumor microenvironment and type I interferon responses, and potentiate the antitumor efficacy of the anti-PD-L1 antibody. Enpp-1-IN-25 can be used in the research of cancer immunotherapy .
Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders .
Enpp-1-IN-10 (compound 1) is a potent Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) inhibitor with an Ki value of 3.866 μM. Enpp-1-IN-10 can be used for researching anticancer .
Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC50=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence .
Enpp-1-IN-7 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-7 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-6 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
Enpp-1-IN-9 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-9 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
Enpp-1-IN-8 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-8 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
Enpp-1-IN-5 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-5 has the potential for the research of cancer and infectious diseases (extracted from patent WO2019046778A1/WO2021203772A1, compound 1) .
Enpp-1-IN-24 (compund 7) is an ENPP1 inhibitor that, in combination with anti-PD-1 antibodies, achieves 77.7% tumor growth inhibition and improves survival in mouse models .
ENPP3 Inhibitor 1 is a selective inhibitor of ENPP3, with IC50s of 0.15 µM (ENPP3) and 41.4 µM (ENPP1) respectively. ENPP3 Inhibitor 1 shows anti-tumor activities against breast cancer and cervical cancer .
Enpp-1-IN-2 (Compound C) is a potent ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) inhibitor with IC50 values of 0.26, 0.48 and 2.0 μM evaluated by means of TG-mAMP, pNP-TMP, and ATP assays, respectively. TG (Tokyo Green)-mAMP: a newly synthesized sensitive ENPP1 fluorescence probe .
Enpp-1-IN-17 (example 274) is a potent ENPP1 inhibitor, with the inhibition constants (Ki values) toward cGAMP and ATP hydrolysis of 100 nM-1 μM and > 1 μM, respectively. The selectivity ratio for inhibition of cGAMP hydrolysis versus ATP hydrolysis is >6.4 .
Enpp/Carbonic anhydrase-IN-2 (compound 1i) is a potent Enpp and carbonic anhydrase inhibitor with IC50s of 1.13, 1.07, 0.74, 0.33, 0.68 for NPP1, NPP2, NPP3, CA-IX, CA-XII respectively. Enpp/Carbonic anhydrase-IN-2 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonic anhydrase-IN-2 induces Apoptosis .
Enpp/Carbonic anhydrase-IN-1 (compound 1e) is a potent Enpp and carbonic anhydrase inhibitor with IC50s of 1.36, 1.35, 3.00, 0.88, 1.02 μM for NPP1, NPP2, NPP3, CA-II, CA-IX respectively. Enpp/Carbonic anhydrase-IN-1 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonic anhydrase-IN-1 induces Apoptosis .
Enpp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Enpp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP6 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP1 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Enpp5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Enpp2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Enpp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Enpp2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP5 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP7 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP2 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Enpp5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP3 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Enpp3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP4 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Enpp3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
AGS-16C3F is an antibody-drug conjugate (ADC) targeting ENPP3. AGS-16C3F is composed of ENPP3-targeting Anti-ENPP3/CD203c Antibody (HY-P990315) linked to Monomethyl auristatin F (HY-15579) via a linker. AGS-16C3F has anti-tumor activity and can be used in the study of metastatic renal cell carcinoma (mRCC) .
NCI-14465 is an ectonucleotide pyrophosphatase/phosphodiesterase (ENPP1) inhibitor with an IC 50 of 26.4 μM. NCI-14465 can be used in cancer research .
ATX inhibitor 11 (compound 13c) is a potent ATX (autotaxin) inhibitor, with an IC50 of 2.7 nM. ATX inhibitor 11 can typically alleviate the severity of fibrosis tissues and effectively reduce the deposition of fibrotic biomarker α-SMA in mice fibrosis model. ATX inhibitor 11 can be used for lung fibrosis research .
CdnP-IN-1 (compound c82) is a potent and selective non-nucleotide MTB CDN PDE (CdnP; Mycobacterium tuberculosis cyclic dinucleotide phosphodiesterase) inhibitor with an IC50 of 18 μM. CdnP-IN-1 does not inhibit the enzymatic activities of three other bacterial CDN PDEs (Yybt, RocR, and GBS-CdnP), a viral CDN PDE (poxin) or mammalian ENPP1 .
ATX inhibitor 9 is a potent inhibitor of ATX. ATX inhibitor 9 is a thickened heteroaryl derivatives compound. Autotaxin (ATX), also known as ENPP2, is a secreted enzyme that is highly expressed mainly in cancer cells, bronchial epithelial cells and alveolar macrophages in the lung. ATX inhibitor 9 has the potential for the research of cancer or fibrous degenerative disease (extracted from patent WO2021078227A1, compound 3) .
Anti-ENPP3/CD203c Antibody (AGS-16C3F antibody) is a humanized antibody expressed in CHO cells, targeting ENPP3/CD203c. Anti-ENPP3/CD203c Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 154.04 kDa. The isotype control for Anti-ENPP3/CD203c Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
ENPP3 is a hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP, and CTP, and plays a key role in immune regulation. It modulates mast cell and basophil responses during inflammation and chronic allergic phases by eliminating extracellular ATP, a trigger for inflammatory cytokine release. ENPP-3 Protein, Macaca fascicularis (HEK293, His) is the recombinant cynomolgus-derived ENPP3 protein, expressed by HEK293 , with N-10*His labeled tag.
ENPP-3 is a hydrolase that metabolizes extracellular nucleotides (ATP, GTP, UTP, CTP), which is critical for immune regulation of inflammation and chronic allergic reactions. By eliminating extracellular ATP, ENPP-3 inhibits basophil and mast cell activation and suppresses the release of inflammatory cytokines. ENPP-3 Protein, Mouse (HEK293, His) is the recombinant mouse-derived ENPP-3 protein, expressed by HEK293 , with N-10*His labeled tag.
ENPP3 is a hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP, and CTP, and plays a key role in immune regulation. It modulates mast cell and basophil responses during inflammation and chronic allergic phases by eliminating extracellular ATP, a trigger for inflammatory cytokine release. ENPP3 Protein, Human (828a.a, HEK293, His) is the recombinant human-derived ENPP3 protein, expressed by HEK293 , with C-10*His labeled tag.
The ENPP-2 protein catalyzes the hydrolysis of lysophospholipids (especially lysophosphatidylcholine) to produce the signaling molecule lysophosphatidic acid (LPA). It also acts on sphingosine phosphocholine to produce sphingosine 1-phosphate, which affects cell movement. ENPP-2 Protein, Human (HEK293, His) is the recombinant human-derived ENPP-2 protein, expressed by HEK293 , with C-6*His labeled tag.
ENPP-1 protein is a nucleotide pyrophosphatase that inhibits excessive hydroxyapatite crystal growth by preferentially hydrolyzing ATP and other nucleoside triphosphates to generate PPi, thereby critically regulating bone mineralization and soft tissue calcification. ENPP-1 Protein, Human (HEK293, His) is the recombinant human-derived ENPP-1 protein, expressed by HEK293 , with C-His labeled tag.
ENPP-3 is a hydrolase that plays a crucial role in regulating the immune response. ENPP-3 plays an important role in tumor development and invasion. The hypomethylation of the ENPP-3 promoter region is involved in the occurrence and progression of ovarian endometriosis through the AKT/mTOR/4EBP1 signaling pathway. ENPP-3 Protein, Canine (HEK293, His) is the recombinant canine-derived ENPP-3 protein, expressed by HEK293 , with N-His labeled tag.
ENPP3 is a hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP, and CTP, and plays a key role in immune regulation. It modulates mast cell and basophil responses during inflammation and chronic allergic phases by eliminating extracellular ATP, a trigger for inflammatory cytokine release. ENPP-3 Protein, Human (318a.a, HEK293, His) is the recombinant human-derived ENPP-3 protein, expressed by HEK293 , with N-His labeled tag.
ENPP3 is a hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP, and CTP, and plays a key role in immune regulation. It modulates mast cell and basophil responses during inflammation and chronic allergic phases by eliminating extracellular ATP, a trigger for inflammatory cytokine release. ENPP-3 Protein, Human (110a.a, HEK293, His-Avi) is the recombinant human-derived ENPP-3 protein, expressed by HEK293 , with N-His, N-Avi labeled tag.
ENPP3 is a hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP, and CTP, and plays a key role in immune regulation. It modulates mast cell and basophil responses during inflammation and chronic allergic phases by eliminating extracellular ATP, a trigger for inflammatory cytokine release. ENPP-3 Protein, Human (Biotinylated, 828a.a, HEK293, His-Avi) is the recombinant human-derived ENPP-3 protein, expressed by HEK293 , with N-His, N-Avi labeled tag.
ENPP3 is a hydrolase that metabolizes extracellular nucleotides, including ATP, GTP, UTP, and CTP, and plays a key role in immune regulation. It modulates mast cell and basophil responses during inflammation and chronic allergic phases by eliminating extracellular ATP, a trigger for inflammatory cytokine release. ENPP-3 Protein, Human (Biotinylated, 110a.a, HEK293, His-Avi) is the recombinant human-derived ENPP-3 protein, expressed by HEK293 , with N-His, N-Avi labeled tag.
ENPP-1 is a nucleotide pyrophosphatase that critically regulates bone mineralization and soft tissue calcification through the production of diphosphate (PPi).This PPi inhibits the growth of hydroxyapatite crystals and prevents unwanted mineralization.ENPP-1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived ENPP-1 protein, expressed by HEK293 , with C-His labeled tag.
ENPP-1 protein is a nucleotide pyrophosphatase that inhibits excessive hydroxyapatite crystal growth by preferentially hydrolyzing ATP and other nucleoside triphosphates to generate PPi, thereby critically regulating bone mineralization and soft tissue calcification. ENPP-1 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived ENPP-1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
ENPP-5, also known as ectonucleotide pyrophosphatase/phosphodiesterase 5, has the ability to hydrolyze nicotinamide adenine dinucleotide (NAD) but does not have lysophospholipase D activity, indicating its inability to hydrolyze Nucleotide diphosphates and triphosphates. This enzymatic activity suggests that ENPP-5 may play a role in regulating NAD levels and possibly affecting cellular processes involved in NAD metabolism. ENPP-5 Protein, Human (HEK293, His) is the recombinant human-derived ENPP-5 protein, expressed by HEK293 , with C-His labeled tag.
The ENPP-7 protein acts as a choline-specific phosphodiesterase and is essential for sphingomyelin digestion, ceramide formation, and FA absorption in the gastrointestinal tract. It hydrolyzes sphingomyelin to release ceramide and phosphocholine. ENPP-7 Protein, Mouse (HEK293, His) is the recombinant mouse-derived ENPP-7 protein, expressed by HEK293 , with C-His labeled tag.
The ENPP-7 protein is a choline-specific phosphodiesterase that plays multiple roles in sphingomyelin digestion, ceramide formation, and fatty acid absorption in the gastrointestinal tract. It hydrolyzes sphingomyelin, releases ceramide and phosphocholine, and promotes the breakdown of sphingomyelin. ENPP-7 Protein, Human (HEK293, His) is the recombinant human-derived ENPP-7 protein, expressed by HEK293 , with C-His labeled tag.
The ENPP-2 protein catalyzes the hydrolysis of lysophospholipids (especially lysophosphatidylcholine) to produce the signaling molecule lysophosphatidic acid (LPA).It also acts on sphingosine phosphocholine to produce sphingosine 1-phosphate, which affects cell movement.ENPP-2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived ENPP-2 protein, expressed by HEK293 , with N-10*His labeled tag.
ENPP-3 is a hydrolase that metabolizes extracellular nucleotides (ATP, GTP, UTP, CTP), which is critical for immune regulation of inflammation and chronic allergic reactions. By eliminating extracellular ATP, ENPP-3 inhibits basophil and mast cell activation and suppresses the release of inflammatory cytokines. ENPP-3 Protein, Rhesus Macaque (sf9, His) is the recombinant Rhesus Macaque-derived ENPP-3 protein, expressed by Sf9 insect cells , with N-His labeled tag.
Enpp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Enpp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP6 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP1 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Enpp5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Enpp2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Enpp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Enpp2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP5 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP7 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP2 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Enpp5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP3 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Enpp3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
ENPP4 Human Pre-designed siRNA Set A contains three designed siRNAs for ENPP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Enpp3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Enpp3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
